Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. develops and commercializes soft-tissue reconstruction solutions for surgeons, with a focus on products designed to preserve and restore patient anatomy while limiting long-term exposure to permanent synthetic materials. Its OviTex portfolio includes configurations used in hernia repair and abdominal wall reconstruction, including ventral, inguinal and hiatal procedures.
Company news commonly covers quarterly and annual results, revenue guidance, commercial execution, product portfolio updates, credit and capital actions, board and leadership changes, and equity compensation grants made under Nasdaq inducement-grant rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TELA Bio, Inc. (NASDAQ: TELA), a leading medical technology company, has announced that it will release its first quarter 2023 financial results on May 11, 2023. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio specializes in innovative soft-tissue reconstruction solutions, aiming to enhance clinical outcomes while preserving the patient's anatomy. Interested investors can register to listen to the call online, with options for a replay available post-event. The company emphasizes its commitment to advanced, economically effective solutions that leverage patients' natural healing responses.
TELA Bio, Inc. announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock at $9.50 per share, aiming for gross proceeds of $45.125 million. This offering will close on April 21, 2023, subject to customary closing conditions. Additionally, underwriters received a 30-day option for 712,500 additional shares. The funds will be utilized for general corporate purposes, including sales and marketing, research and development, and working capital. The offering is made under an effective shelf registration statement.